Replies to post #17271 on GT Biopharma Inc (GTBP)

[MysticMonk]

Awesome! GTBP OXS-1550 shows positive action in Phase 1/2 blood cancer study..

54% (n=7/13) of patients experienced clinical benefit, including one complete responder, one partial responder and five with stable cancer.

In ALL patients, 75% (n=3/4) experienced clinical benefit (one complete responder, one partial responder and one with stable cancer).